Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist

Pharmaceutical Development and Technology

Volumn 19, Issue 3, 2014, Pages 278-284

  Akash, Muhammad Sajid Hamid ^a,b   Rehman, Kanwal ^a   Sun, Hongying ^a   Chen, Shuqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

Author keywords

DSC; FTIR; Pluronic F127; Poloxamer 407; Stability of IL 1Ra; Sustained release of IL 1Ra

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; POLOXAMER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; GEL; GELATION; HEAT SENSITIVITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONTENT; TEMPERATURE; THERMOSTABILITY; VISCOSITY;

DELAYED-ACTION PREPARATIONS; GELS; KINETICS; POLOXAMER; RECEPTORS, INTERLEUKIN-1; TEMPERATURE;

EID: 84897979761     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.775158     Document Type: Article

References (32)

1. Strappe PM, Hampton DW, Cachon-Gonzalez B, et al. Delivery of a lentiviral vector in a Pluronic F127 gel to cells of the central nervous system. Eur J Pharm Biopharm 2005;61:126-33.
2. Jain N, Aswal P, Goyal P, Bahadur P. Micellar structure of an ethylene oxide-propylene oxide block co-polymer. A small angle neutron scattering study. J Phys Chem 1998;102:8452-60.
3. Stratton LP, Dong A, Manning M, Carpenter JF. Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel. J Pharm Sci. 1997;86:1006-10.
4. Morishita M, Barichello JM, Takayama K, et al. Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin. Int J Pharm 2001;212:289-93.
5. Akash MSH, Rehman K, Li N, et al. Sustained delivery of IL-1Ra from Pluronic F127-based thermosensitive gel prolongs its therapeutic potentials. Pharm Res 2012;29:3475-85.
6. Wang PL, Johnston TP. Enhanced stability of two model proteins in an agitated solution environment using poloxamer 407. J Parenter Sci Technol 1993;47:183-9.
7. Das N, Madan P, Lin S. Statistical optimization of insulin-loaded Pluronic F-127 gels for buccal delivery of basal insulin. Pharm Dev Technol 2012;17:363-74.
8. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis 1999;58:196-8.
9. Dayer JM, Feige U, Edwards CK, Burger D. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001;13: 170-6.
10. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356: 1517-26.
11. Akash MSH, Rehman K, Sun H, Chen S. Sustained delivery of IL-1Ra from PF127 gel reduces hyperglycemia in diabetic GK rats. PLoS One 2013;8:e55925.
12. Ehses JA, Lacraz G, Giroix M, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009;106:13998-4003.
13. Akash MSH, Rehman K, Sun H, Chen S. Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats. Eur J Pharmacol 2013;701:87-95.
14. Akash MSH, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 2012;101:1647-58.
15. Zhang Y, Huo M, Zhou J, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J 2010;12:263-71.
16. Varshosaz J, Tabbakhian M, Salmani Z. Designing of a thermosensitive Chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin. Open Drug Deliv J 2008;2:61-70.
17. Zhang Y, Roy S, Jones LS, et al. Mechanism for benzyl alcoholinduced aggregation of recombinant human interleukin-1receptor antagonist in aqueous solution. J Pharm Sci 2004;93:3076-89.
18. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm 1999;184:189-98.
19. Kikwai L, Babu RJ, Prado R, et al. In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech 2005;6: 565-72.
20. Chaibva FA, Walker RB. The comparison of in vitro release methods for the evaluation of oxytocin release from pluronic f127 parenteral formulations. Dissolut Technol 2007;14:15-26.
21. Hiwale P, Lampis S, Conti G, et al. In vitro release of lysozyme from gelatin microspheres: effect of cross-linking agents and thermoreversible gel as suspending medium. Biomacromolecules 2011;12: 3186-93.
22. Price NC. Conformational issues in the characterization of proteins. Biotechnol Appl Biochem 2000;31:29-40.
23. Hyun H, Kim YH, Song IB, et al. In vitro and in vivo release of albumin using a biodegradable MPEG-PCL diblock copolymer as an in situ gel-forming carrier. Biomarcomolecules 2007;78:1093-100.
24. Wannachaiyasit S, Phaechamud T. Development of chlorhexidine thermosensitive gels as a mouth antiseptic. J Metals Mater Miner 2010;20:165-8.
25. Nie S, Hsiao WW, Pan W, Yang Z. Thermosensitive pluronic F127-based hydrogel containing liposomes for the controlled delivery of paclitaxel: in vitro drug release, cell cytotoxicity, and uptake studies. Int J Nanomed 2011;6:151-61.
26. Zhang L, Parsons DL, Navarre C, Kompella UB. Development and in-vitro evaluation of sustained release Poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 2002;85:73-81.
27. Liu Y, Lu WL, Wang JC, et al. Controlled delivery of recombinant hirudin based on thermosensitive pluronic F127 hydrogel for subcutaneous administration: in vitro and in vivo characterization. J Control Release 2007;117:387-95.
28. Akash MSH, Rehman K, Rasool F, et al. Alternate therapy of type 2 diabetes mellitus (T2DM) with Nigella (Ranunculaceae). J Med Plants Res 2011;5:6885-9.
29. Akash MSH, Rehman K, Chen S. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J Cell Biochem 2012;114:525-31.
30. Remmele RL, Nightlinger NS, Srinivasan S, Gombotz WR. Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 1998;15:200-8.
31. Kang F, Jiang G, Hinderliter A, et al. Lysozyme stability in primary emulsification for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm Res 2002;19:629-33.
32. Katakam M, Banga AK. Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses. Pharm Dev Technol 1997;2:143-9.